Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;17(5):25.
doi: 10.1007/s11864-016-0400-x.

Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer

Nam Bui  1 , Brian Woodward  2 , Anna Johnson  2 , Hatim Husain  3   4   5
Affiliations
Review

Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer

Nam Bui et al. Curr Treat Options Oncol. 2016 May.

Abstract

Brain metastases are common in patients with non-small cell lung cancer (NSCLC), and due to associated poor prognosis, this field is an important area of need for the development of innovative medical therapies. Therapies including local approaches through surgical intervention and/or radiation and evolving systemic therapies have led to improvements in the treatment of brain metastases in patients with lung cancer. Strategies that consider applying advanced radiation techniques to minimize toxicity, intervening early with effective systemic therapies to spare radiation/surgery, testing radiosensitization combinations, and developing drug penetrant molecules have and will continue to define new practice patterns. We believe that in carefully considered asymptomatic patients, first-line systemic therapy may be considered before radiation therapy and small-molecule targeted therapy may provide an opportunity to defer radiation therapy for recurrence or progression of disease. The next several years in oncology drug development will see the reporting on of brain penetrant molecules in oncogene-defined non-small cell lung cancer. Ongoing studies will evaluate immunotherapies in patients with brain metastases with associated endpoints. We hope that continued drug development and carefully designed clinical trials may afford an opportunity to improve the lives of patients with brain metastases.

Keywords: Blood-brain barrier; Brain metastases; Chemotherapy; Immunotherapy; Lung cancer; Radiation; Targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. N Engl J Med. 2015 Oct 22;373(17):1627-39 - PubMed
    1. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003869 - PubMed
    1. Cancer Res. 2005 Apr 15;65(8):3328-35 - PubMed
    1. J Med Chem. 2014 Jun 12;57(11):4720-44 - PubMed
    1. Lancet Oncol. 2014 Sep;15(10):1119-28 - PubMed

Substances

LinkOut - more resources